Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | MAOB | P27338 | 4/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12210768 | 0.86 | MAPT (0.60) | MAPTALDH1A1LMNAKMT2AATM | |
| SCHEMBL4986888 | 0.84 | MAPT (0.71) | KDM4EMAPTMAOBSIGMAR1ALDH1A1 | |
| SCHEMBL4014456 | 0.83 | MAPT (0.68) | KDM4EMAPTALDH1A1LMNAKMT2A | |
| SCHEMBL2890893 | 0.83 | MAPT (0.51) | KDM4EMAPTMAOBSIGMAR1HRH3 | |
| SCHEMBL15923825 | 0.82 | MAPT (0.56) | MAPTALDH1A1LMNAKMT2AATM | |
| SCHEMBL30380932 | 0.82 | CHRNB2 (0.58) | KDM4EMAPTHRH3ALDH1A1LMNA | |
| SCHEMBL1283404 | 0.82 | KDM4E (0.44) | KDM4EMAOBSIGMAR1HRH3MAOA | |
| SCHEMBL1962346 | 0.82 | CHRNB2 (0.58) | KDM4EMAPTHRH3ALDH1A1LMNA | |
| SCHEMBL4983657 | 0.82 | KDM4E (0.66) | KDM4EMAPTMAOBSIGMAR1ALDH1A1 | |
| SCHEMBL4986148 | 0.81 | KDM4E (0.48) | KDM4EMAPTMAOBSIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286197-A1 | Carboxamide Derivatives As Therapeutic Agents | TRANSTECH PHARMA, INC. | 2010-11-11 | — | — | US | disclosed |
| US-7776919-B2 | Carboxamide derivatives as therapeutic agents | TransTech Pharm, Inc. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7423177-B2 | Carboxamide derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080119512-A1 | Carboxamide Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119534-A1 | Benzimidazole Derivatives as Therapeutic Agents | TRANS TECH PHARMA, INC (US) | 2008-05-22 | — | — | US | disclosed |
| US-7329684-B2 | Benzimidazole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1377295-A4 | CARBOXAMIDE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC (US) | 2007-05-09 | — | — | EP | disclosed |
| US-7087632-B2 | Benzimidazole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060025464-A1 | Benzimidazole derivatives as therapeutic agents | TRANSTECH PHARMA, LLC | 2006-02-02 | — | — | US | disclosed |
| EP-1387680-A1 | BENZIMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TransTech Pharma Inc. (US) | 2004-02-11 | — | — | EP | disclosed |
| EP-1377295-A2 | CARBOXAMIDE DERIVATIVES AS THERAPEUTIC AGENTS | Transtech Pharma, Inc. (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030032663-A1 | Benzimidazole derivatives as therapeutic agents | TRANSTECH PHARMA, LLC | 2003-02-13 | — | — | US | disclosed |
| US-20020193432-A1 | Carboxamide derivatives as therapeutic agents | VTVX HOLDINGS I LLC | 2002-12-19 | — | — | US | disclosed |
| WO-2002070473-A2 | CARBOXAMIDE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002069965-A1 | BENZIMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286197-A1 | Carboxamide Derivatives As Therapeutic Agents | AGER, S100B, S100A4 | KDM4E 2929/4885MAPT 655/4885MAOB 2008/4885 |
| US-20080119534-A1 | Benzimidazole Derivatives as Therapeutic Agents | AGER, S100B, S100A4 | KDM4E 3269/4885MAPT 539/4885MAOB 1721/4885 |
| US-20030032663-A1 | Benzimidazole derivatives as therapeutic agents | AGER, S100B, S100A4 | KDM4E 3282/4885MAPT 474/4885MAOB 1747/4885 |
| US-20020193432-A1 | Carboxamide derivatives as therapeutic agents | AGER, S100B, S100A4 | KDM4E 2900/4885MAPT 624/4885MAOB 2088/4885 |
| US-20060025464-A1 | Benzimidazole derivatives as therapeutic agents | AGER, S100B, S100A4 | KDM4E 3269/4885MAPT 539/4885MAOB 1721/4885 |
| US-20080119512-A1 | Carboxamide Derivatives as Therapeutic Agents | AGER, S100B, S100A4 | KDM4E 2929/4885MAPT 655/4885MAOB 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.